Riskpilot← Back to searchSign inGet full accessTMOS PHARMA AS
ASActiveOrg 920648088Camilla Colletts Veg 31, 2407 ElverumWholesale of pharmaceutical and medical goods · NACE 4646Est. 20181 employees
Revenue 2024
NOK 1,4M
-30% vs 2023
EBITDA margin
-21.6%
+19% vs 2023
Equity ratio
-9.5%
Financial strength
Net profit 2024
NOK -433K
0% vs 2023
| Revenue | NOK 1,4M | -30% |
| EBITDA | NOK -308K | +19% |
| Net profit | NOK -433K | +0% |
| Total assets | NOK 1,2M | -31% |
| Equity | NOK -114K | -136% |
| Employees | 1 | — |
Legal name
TMOS PHARMA AS
Org number
920648088
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22. mars 2018
Share capital
NOK 43 424
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Engroshandel med sykepleie- og apotekvarer og konsulentvirksomhet i tilknytning til dette og andre produkter/tjenester som naturlig hører sammen med dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Camilla Colletts Veg 31, 2407 Elverum
Phone
+4762426280
Email
info@tmos.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 757 | 2 083 | 3 184 | 2 262 | 2 033 | 1 423 |
| Staff expenses | −485 | −1 665 | −997 | −953 | −469 | −328 | −131 |
| EBITDA | −693 | −3 549 | −1 397 | −873 | −1 056 | −380 | −308 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −693 | −3 549 | −1 397 | −873 | −1 056 | −380 | −308 |
| Net financials | −13 | −99 | −94 | 1 464 | −67 | −52 | −125 |
| Profit before tax | −706 | −3 648 | −1 492 | 591 | −1 123 | −432 | −433 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −706 | −3 648 | −1 492 | 591 | −1 123 | −432 | −433 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 2 344 | 3 148 | 2 663 | 3 083 | 2 324 | 1 728 | 1 200 |
| Equity | −683 | 1 229 | 1 280 | 1 874 | 750 | 319 | −114 |
| Long-term debt | 0 | 900 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 028 | 1 019 | 1 383 | 1 209 | 1 574 | 1 409 | 1 314 |
| Total debt | 3 028 | 1 919 | 1 383 | 1 209 | 1 574 | 1 409 | 1 314 |
EBITDA margin
-21.6%
This company
15.8%
Market median
-237% vs market
20182024
Equity ratio
-9.5%
This company
38.2%
Market median
-125% vs market
20182024
Return on equity
-43264800.0%
This company
18.4%
Market median
-235134883% vs market
20182024
Net profit margin
-30.4%
This company
8.1%
Market median
-475% vs market
20182024
Asset turnover
1.19×
This company
1.12×
Market median
+6% vs market
20182024
Debt / equity
11.53×
This company
0.62×
Market median
-1760% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-03-13 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ÅB Deputy Member | Deputy Member | 2023 | — | — |
SH Deputy Member | Deputy Member | 2023 | — | — |
TM Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
TM Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Tmos Holding As | Company | 63.4% | 63.4% | 2024 |
| Individual | 6.2% | 6.2% | 2024 | |
| Individual | 5.7% | 5.7% | 2024 | |
| Individual | 4.8% | 4.8% | 2024 | |
Fagflis Elverum As Byggmester Ivar Bakke | Company | 4.8% | 4.8% | 2024 |
Mht Hauge As | Company | 3.5% | 3.5% | 2024 |
STEINBUA ELVERUM AS | Company | 3.3% | 3.3% | 2022 |
| Individual | 3.3% | 3.3% | 2024 | |
| Individual | 1.5% | 1.5% | 2024 | |
| Individual | 1.4% | 1.4% | 2022 | |
Agito Group As | Company | 1.3% | 1.3% | 2024 |
| Individual | 1.2% | 1.2% | 2024 | |
| Individual | 1.2% | 1.2% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TMOS PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Åsmund Bakke | Deputy Member | 0 companies |
| Stein Hauge | Deputy Member | 0 companies |
| Tore Martin Olden Stensberg | Chief Executive Officer | 0 companies |
| Tore Martin Stensberg | Chief Executive Officer | 0 companies |
| Mari Olden Stensberg | Board of Directors | 0 companies |
| Amund Grindalen | Chairman | 0 companies |
| Mari Hammersborg Olden | Board of Directors | 0 companies |